Navigation Links
Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
Date:3/13/2008

NEW YORK, March 13 /PRNewswire/ -- Biologics and derma fillers are driving significant growth in the prescription dermatological drug market, due in large part to new products and technology developments. The market was valued at $8.9 billion in 2006 and is expected to achieve a CAGR of 7% through 2011, lead by the anti-aging/photo-damage, hair treatment, psoriasis and skin cancer treatment segments, according to Kalorama Information's new report Prescription Dermatological Drugs: Worldwide Market, 6th Edition.

"There are impressive new options for the treatment of aging skin, acne, psoriasis and a host of other conditions -- including bio-engineered collagen, hydroxyapatite fillers and new biologic agents," notes Mary Ann Crandall, the author of the report. "These have moved from promising developments to viable treatment alternatives."

New fillers include bio-engineered human injectable collagen, replacing bovine collagen which was plagued with short-lived results and allergic reactions, as well as hyaluronic acid gel, a new non-animal soft tissue filler that was recently approved in the United States. For longer-lasting results there is the new filler hydroxyapatite with a methylcellulose vehicle and a recently approved permanent injectable called polymethylmethacrylate. A new medical grade form of silicone is also being studied to determine its safety and efficacy as a permanent filler.

With the advent of recombinant deoxyribonucleic acid technology and advances in microbiology and immunology, the biologics field is expanding rapidly and dermatology is a primary focus for the development of new agents. Biologics are expected to dominate the psoriasis market with a 70% market share by 2011, due to the introduction of several new biologic immune modulators. A number of other skin diseases are also good candidates for biologic therapy, namely atopic dermatitis and cutaneous T-cell lymphomas.

Kalorama Information's report Prescription Dermatological Drugs: Worldwide Market, 6th Edition discusses critical issues and trends and provides updated market information for 2001 to 2011. The information presented is the result of interviews conducted with over 45 industry executives and data gathered through secondary research. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Prescription-Dermatological-Drugs-139953 2/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramainformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
2. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
3. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
4. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
5. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
6. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
9. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... WOODLANDS, Texas , May 3, 2016  Dr. ... certified plastic surgeon in The Woodlands, Texas ... that destroys 24 percent of treated fat cells in ... and woman. Close to 90 percent of Americans report ... treatment options. Nonsurgical fat reduction procedures are a growing ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... in mind, the fresh look and added functionality give the agricultural world a ... seen a dynamic shift in agriculture – from precision farming via satellites and ...
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell ... the development of a patient-specific stem cell therapy for the treatment of Parkinson’s disease. ... Dr. Jeanne Loring at The Scripps Research Institute in San Diego, CA. ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/18/2016)... , March 18, 2016 --> ... of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and ... security companies in the border security market and the continuing ... and Europe has led visiongain to ... improved success. --> defence & security companies ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
Breaking Biology News(10 mins):